drugset / Trial / NCT00366171

Open Label Extension Study of Bifeprunox

NCT00366171

Phase 3 Completed 120 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.

Timeline

Start
2006-11
Primary completion
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bifeprunox Small molecule 20 mg
Subject Bifeprunox Small molecule 30 mg

Indications